Correction to: Development and validation of a modified albumin-bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab

Hepatol Int. 2023 Feb;17(1):271-273. doi: 10.1007/s12072-022-10446-0. Epub 2022 Nov 16.
No abstract available

Publication types

  • Published Erratum